The aspirin resistance and platelets` receptors expression in chronic heart failure patients with type 2 diabetes mellitus

Authors

DOI:

https://doi.org/10.14739/2310-1210.2014.3.25594

Keywords:

Aspirin, Drug Resistance, Chronic Disease, Heart Failure, Platelet Activation, Type 2 Diabetes Mellitus

Abstract

Introduction. Chronic heart failure (CHF) is a complex clinical syndrome associated with high mortality rates. The presence of type 2 diabetes mellitus (DM) is an independent unfavourable prognostic factor in heart failure patients. Chronic heart failure and type 2 diabetes mellitus are closely inter-related conditions through different pathological mechanisms, including platelet activation. The presence of DM in CHF patients can dramatically increase platelet dysfunction. The problem is much complicated by high level of aspirin resistance in diabetic patients. The prevalence of aspirin resistance in CHF with DM has never been studied.

The aim of our research was to estimate the prevalence of aspirin resistance in heart failure patients with type 2 diabetes mellitus and to clarify platelets` abnormalities according to glycemic control status.

Materials and methods. The criteria for study inclusion were: a more than 1-year documented history of CHF due to coronary artery disease, sinus rhythm, type 2 diabetes mellitus, no change in medication for > 3 months, daily aspirin use 100 mg > 6 months. All patients had previous history of myocardial infarction. Exclusion criteria were: type 1 DM, patients with type 2 DM on insulin therapy and/or thiazolidinediones, major bleedings in anamnesis, chronic renal failure, chronic obstructive pulmonary disease, autoimmune diseases, significant liver failure, cancer. We studied 65 patients with heart failure and type 2 diabetes mellitus (mean age 62±8 years). The control population comprised 35 heart failure patients without diabetes mellitus (mean age 60±9 years). Platelet function was evaluated using standard light transmission aggregometry. Aspirin resistance was defined by known criteria: ≥ 70% ADP- and ≥ 40% epinephrine-induced aggregation. Measurements of CD41, CD41a, CD61 and CD62P were carried out by fluorescent microscopy study. The plasma levels of soluble P-selectin and soluble CD40L were measured by ELISA assays.

Results. Age, sex, severity of CHF, left ventricular ejection fraction (LVEF), estimated glomerular filtration rate and cardiovascular treatment were comparable between three groups. Hypertension rate was slightly frequent in patients with CHF and decompensated DM. The patients with CHF and decompensated DM had higher fasting plasma glucose, HbA1cand HOMA-IR levels. The duration of the diabetes was similar. Glucose lowering treatment on admission was comparable between groups. The rate of aspirin resistance was tend to be higher in patients with CHF and DM (by ADP-induced aggregation: 23.1% in diabetic patients vs. 14.3% in non-diabetic patients, P=0.43; by epinephrine-induced aggregation: 36.9% in diabetic patients vs. 31.4% in non-diabetic patients, P=0.66), but the difference was not statistically significant. The compensation of DM didn’t influence on aspirin resistance rate also. The compensation of DM didn’t influence on aspirin resistance rate also. No significant changes in platelets’ parameters were observed between CHF patients without DM and patients with CHF and compensated DM. In contrast, the patients with CHF and decompensated DM presented higher platelet surface CD62P, CD41, CD41a and CD61 expression in comparison to CHF patients without DM. The patients with CHF and HbA1c of more than 7 % showed also higher plasma P-selectin and higher platelet surface CD41 and CD61 expression compared with CHF patients with HbA1c of less than 7 %. Plasma sP-selectin correlated positively with FPG, insulin, C-peptide and HOMA-IR. Platelet surface P-selectin correlated only with C-peptide. Both IIb and IIIa glycoprotein receptors correlated with HbA1c. Conclusions. The rate of aspirin resistance varies from 23 to 37% in patients with chronic heart failure and type 2 diabetes mellitus depending on tests used. Platelet reactivity is associated with glycemic control status in heart failure diabetic patients on long-term aspirin therapy.

 

References

Askoxylakis, V., Thieke, C., Pleger, S. T., Most, P., Tanner, J., Lindel, K., et al. (2010) Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer, 10, 105–115. doi:10.1186/1471-2407-10-105.

Shaw, J., Sicree, R., & Zimmet, P. (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diab Res and Clin Pract, 87, 4–14. doi: 10.1016/j.diabres.2009.10.007.

Baliga, V., & Sapsford, R. (2009) Diabetes and heart failure: an overview of epidemiology and management. Diab Vasc Dis Res, 6,164–171. doi: 10.1177/1479164109338773.

Serebruany, V., Malinin, A., Jerome, S., Lowry, D., Morgan, A., Sane, D., et al. (2003) Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. Am Heart J, 146, 713–720.

Gibbs, C., Blann, A., Watson, R., & Lip, G. (2001) Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm. Circulation, 103, 1746–1751.

Gurbel, P., Gattis, W., Fuzaylov, S., Gaulden, L., Hasselblad, V., Serebruany, V., & O`Connor, C. (2002) Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes? Am Heart J, 143, 1068–1075.

Fateh-Moghadam, S., Plöckinger, N., & Cabeza, S. (2005) Prevalance of aspirin resistance in patients with type 2 diabetes. Acta Diabetol, 42, 99–103. doi:10.1007/s00592-005-0186-y.

Ferroni, P., Basili, S., Falco, A., & Davi, G. (2004) Platelet activation in type 2 diabetes mellitus. J Thromb Haemost, 2, 1282–1291. doi: 10.1111/j.1538-7836.2004.00836.x.

Dunn, E., Ariens, R., & Grant, P. (2005) The influence of type 2 diabetes on fibrin structure and function. Diabetologia, 48, 1198–1206. doi: 10.1007/s00125-005-1742-2.

Levey, A. S., Bosch, J. P., Lewis, J. B, Greene, T, Rogers, N., & Roth, D. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med, 130, 461–470.

Cazenave, J., Hemmendinger, S., Beretz, A., Sutter-Bay, A., Launay, J. (1983) Platelet aggregation: a tool for clinical investigation and pharmacological study. Methodology Ann Biol Clin, 41, 167–179.

Gibbins, J. M., & Mahaut-Smith, M. P. (2004) Preparation of washed platelet suspensions from human and rodent blood. Platelets and megakaryocytes.

J. M. Walker (Ed.). Totowa ; New Jersey: Humana Press, (p. 13–28).

Gum, P., Kottke-Marchant, K., Welsh, P., White, J., & Topol, E. (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol, 41, 961–965. doi:10.1016/S0735-1097(02)03014-0.

Stef, G., Csiszar, A., Lerea, K., Ungvari, Z., & Veress, G. (2006) Resveratrol inhibits aggregation of platelets from high-risk cardiac patients with aspirin resistance. J Cardiovasc Pharmacol, 48, 1–5.

Krasopoulos, G., Brister, S. J., Beattie, W. S., & Buchanan, M. R. (2008) Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ, 336, 195 doi:10.1136/bmj.39430.529549.BE.

Schneider, D. J., Hardison, R. M., Neuza, L., Sobel, B. E., & Brooks, M. M. (2009) Association between platelet P-selectin expression and obesity in patients with type 2 diabetes. Diabetes Care, 32, 944–949.

Cleland, J. G., Findlay, I., Jafri, S., Sutton, G., Falk, R., Bulpitt, C., et al. (2004). The Warfarin/Aspirin Study in Heart Failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J, 148, 157–164.

Massie, B. M., Collins, J. F., Ammon, S. E., Armstrong, P. W., Cleland, J. G. F., Ezekowitz, M., et al. (2009) The Warfarin and antiplatelet therapy in chronic heart failure (WATCH) trial. Circulation, 119, 1616–1624.

Cleland, J. G. F., Ghosh, J., Freemantle, N., Kaye, G. C., Nasir, M., Clark, A. L., & Coletta, A. P. (2004) Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-LIPIDS and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail, 6, 501–508. doi:10.1016/j.ejheart.2004.04.014.

Lim, H. S., Blann, A. D., & Lip, G. Y. H. (2004) Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus. Circulation, 109, 2524–2528. doi: 10.1161/01.CIR.0000129773.70647.94.

Ajjan, R., & Grant, P. J. (2006) Coagulation and atherothrombotic disease. Atherosclerosis, 186, 240–259.

Macchi, L., Christiaens, L., & Severine, B. S. (2002) Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res, 107, 45–49.

Osende, J. I., Badimon, J. J., Fuster, V., Herson, P., Rabito, P., Vidhun, R., et al. (2001) Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol , 38, 1307–1312. doi:10.1016/S0735-1097(01)01555-8.

Keating, F. K., Sobel, B. E., & Schneider, D. J. (2003) Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. Am J Cardiol, 92, 1362–1365.

Collier, A., Watson, H. H., Patrick, A. W., Ludlam, C. A., & Clarke, B. F. (1989) Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabete Metab, 15, 420–425.

Gregorio, F., Ambrosi, F., Manfrini, S., Velussi, M., Carle, F., & Testa, R. (1999) Poorly controlled elderly type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin. Diabet Med, 16, 1016–1024.

Nagi, D. K., & Yudkin, J. S. (1993) Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care, 16, 621–629.

Downloads

How to Cite

1.
Kolesnyk MY, Syvolap VV. The aspirin resistance and platelets` receptors expression in chronic heart failure patients with type 2 diabetes mellitus. Zaporozhye Medical Journal [Internet]. 2014Jul.4 [cited 2024Nov.23];16(3). Available from: http://zmj.zsmu.edu.ua/article/view/25594

Issue

No. 3 (2014): Zaporozhye medical journal

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)